OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, "OpGen" or "the Company") announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the "SEC"). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.
馬里蘭州羅克維爾，2024年4月23日（GLOBE NEWSWIRE）——OPGen, Inc.（納斯達克股票代碼：OPGN，“OPGen” 或 “公司”）今天宣佈，它收到了納斯達克股票市場有限責任公司（“納斯達克”）的通知，表明該公司未遵守納斯達克上市規則5250（c）（1），原因是該公司未提交截至財年的10-K表年度報告 2023 年 12 月 31 日（“10-K 表格”）。《納斯達克上市規則》第5250（c）（1）條要求上市公司及時向美國證券交易委員會（“SEC”）提交所有定期報告。該公司此前曾向美國證券交易委員會提交了12b-25表格，披露如果沒有不合理的努力或費用，該公司無法在2024年4月1日之前提交10-K表格。
The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the "Minimum Bid Price Rule"). As previously disclosed, on February 9, 2024, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance. If the Nasdaq Hearings Panel continues to permit the Company the additional period to regain compliance, the Company expects that it will be required by Nasdaq to file the Form 10-K no later than June 3, 2024 to avoid a delisting determination.
該公司此前曾收到納斯達克的書面通知，稱其未能連續30個工作日維持每股1.00美元的最低出價（“最低出價規則”），因此未遵守納斯達克上市規則5550（a）（2）。正如先前披露的那樣，該公司於2024年2月9日收到納斯達克的書面通知，納斯達克聽證會小組已批准該公司在2024年6月3日之前恢復遵守最低出價規則。最新的通知規定，納斯達克聽證會小組將考慮拖欠的10-K表格，同時考慮其先前給予的額外期限以恢復合規性。如果納斯達克聽證會小組繼續允許公司延長恢復合規的期限，該公司預計納斯達克將要求其在2024年6月3日之前提交10-K表格，以避免退市決定。
The notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule.
該通知對公司普通股在納斯達克的上市或交易沒有立即影響。儘管公司無法保證時機，但該公司正在努力完成10-K表格，並計劃儘快提交10-K表格，以恢復對納斯達克上市規則的遵守。
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. The Company distributes molecular microbiology solutions that help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
關於 OpGen, Inc.
OpGen, Inc.（美國馬里蘭州羅克維爾）是一家精準醫療公司，利用分子診斷和生物信息學的力量來幫助對抗傳染病。該公司分發分子微生物學解決方案，幫助指導臨床醫生更快速、更具操作性的有關危及生命的感染的信息，以改善患者的預後，減少由耐多藥微生物（mDRO）引起的感染的傳播。
For more information, please visit www.opgen.com
欲了解更多信息，請訪問 www.opgen.com
Forward-Looking Statements
前瞻性陳述
This press release includes statements regarding a notice of non-compliance received from Nasdaq. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to timely complete our financial reporting processes with the Company's auditors and file the Form 10-K, the impacts of other unanticipated delays to the Company's financial reporting process or other violations of Nasdaq Listing Rules, our ability to regain compliance with Nasdaq Listing Rules, our ability to continue to finance our business and operations, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
本新聞稿包括有關從納斯達克收到的違規通知的聲明。根據1933年《證券法》第27A條和1934年《證券交易法》第21E條的定義，這些陳述和其他有關OpGen未來計劃和目標的陳述構成了 “前瞻性陳述”，旨在使他們有資格獲得避風港，免於承擔1995年《私人證券訴訟改革法》規定的責任。此類陳述存在風險和不確定性，這些風險和不確定性通常難以預測，超出我們的控制範圍，並可能導致結果與預期存在重大差異。可能導致我們的業績與上述業績存在重大差異的因素包括但不限於我們及時與公司核數師一起完成財務報告流程並提交10-K表格的能力、公司財務報告流程其他意外延遲或其他違反《納斯達克上市規則》的行爲的影響、我們恢復遵守納斯達克上市規則的能力、我們繼續爲業務和運營融資的能力以及我們的流動性和營運資金要求。要討論與OpGen業務相關的最重大風險和不確定性，請查看我們向美國證券交易委員會提交的文件。提醒您不要過分依賴這些前瞻性陳述，這些陳述基於我們截至本新聞稿發佈之日的預期，僅代表截至本新聞稿發佈之日的預期。我們沒有義務公開更新或修改任何前瞻性陳述，無論是由於新信息、未來事件還是其他原因。
OpGen:
David E. Lazar
CEO
InvestorRelations@opgen.com
OpGen：
大衛·拉扎爾
首席執行官
InvestorRelations@opgen.com
Source: OpGen, Inc.
來源：OpGen, Inc.
譯文內容由第三人軟體翻譯。